Liberty Wealth Management LLC Increases Its Share Position in Johnson & Johnson (NYSE:JNJ)

VaselineSeptember 11, 2024

0 4 minutes read

Liberty Wealth Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 680.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 16,396 shares of the company’s stock after acquiring an additional 14,296 shares during the period. Liberty Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,396,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Inçalta Capital LLC purchased a new stake in Johnson & Johnson in the second quarter worth approximately $27,000. Christopher J. Hasenberg Inc purchased a new position in shares of Johnson & Johnson in the first quarter valued at approximately $31,000. Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $44,000. MFA Wealth Advisors LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $43,000. Finally, Grayhawk Investment Strategies Inc. raised its stake in shares of Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares in the last quarter. 69.55% of the shares are currently owned by institutional investors and hedge funds.

The Wall Street analyst weighs in

A number of research firms recently issued reports on JNJ. Goldman Sachs Group cut their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, September 6th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a report on Tuesday. July 23. Finally, Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $173.21.

Want more great investment ideas?

Check out our latest review on JNJ

Johnson & Johnson price performance

Shares of JNJ stock opened at $167.38 on Wednesday. The company has a 50-day simple moving average of $158.40 and a 200-day simple moving average of $153.85. The company has a market cap of $402.92 billion, a P/E ratio of 10.44, a PEG ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a current ratio of 1.07, a quick ratio of 0.85, and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period last year, the firm posted EPS of $2.80. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, equities analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents an annualized dividend of $4.96 and a dividend yield of 2.96%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Insider trading at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which is accessible via this link. Company insiders own 0.16% of the company’s shares.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.